New treatment strategies in patients with impaired left ventricular systolic function. Part II: Treatment of moderate to severe cardiac dysfunction.
Rozo
J C
JC
Division of Cardiology, University of Texas Medical Branch at Galveston, 77555-1064, USA.
Barry
W L
WL
Stouffer
G A
GA
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use; D004077:Digoxin / Q000627:therapeutic use; D006801:Humans; D012720:Severity of Illness Index; D013599:Systole; D018487:Ventricular Dysfunction, Left / Q000175:diagnosis / Q000188:drug therapy*
D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D002121:Calcium Channel Blockers; D002316:Cardiotonic Agents; D004077:Digoxin